Gene Editing in T Cells for Cancer

We believe our genome editing technologies have the potential to improve the characteristics of cellular therapies, including engineered T cells to treat cancer. There have been encouraging early signs that engineered T cells may have potential against a number of cancers and patients. Recent data suggest that increasing the length of time that T cells are active in the body (T cell persistence) may help destroy tumors. 

At Editas Medicine, we believe that our genome editing technology has the potential to improve T cell persistence, as well as other important characteristics of engineered T cells. If we are successful, we may be able to significantly expand the kinds of cancers that can be treated by chimeric antigen receptor/T cell receptor (CAR/TCR) engineered T cells and improve the outcome of these therapies.

Juno Collaboration

In May 2015, we entered into collaboration with Juno Therapeutics, a leader in the emerging field of immuno-oncology. Together, our efforts aim to improve the efficacy and safety of chimeric antigen receptor/T cell receptor (CAR/TCR) engineered T cells against a range of tumor types. Our current efforts are focused on optimizing our genome editing components and delivery methods that are compatible with engineered T cell manufacturing methods developed by Juno Therapeutics. Together, we hope to discover and develop the next generation of engineered T cell therapies with the potential to substantially advance the field of cancer immunotherapy.